OA Univ.-Prof. Mag. DDr. Klaus Podar

Back to overview

Head of
Department of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)

Research projects

To the research portal KRIS

PROTACs

Targeting Transcription factors for cancer therapy utilizing PROteolysis-TArgeting Chimera (PROTACs)

STAT3

STAT3 isoforms in hematopoietic disorders

Functional analysis of JunB-mediated immunosuppression

Biomarker- based therapeutic prevention

Biomarker- based therapeutic prevention of bone metastases in breast cancer. Defining the pathophysiologic impact of the endosteal niche

Publication

To the research portal KRIS

Conference contribution to journal

2025

Fan, F., Jiang, S., Ni, E., Wang, Z., Wang, Y., Zuo, L., Ma, C., Vallet, S., Xu, A., Xu, J., Podar, K., Sun, C., & Hu, Y. (2025). DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma. Blood, 146(Supplement 1), 3944-3944.

Journal article

2025

Oudaert, I., van den Broecke, L., Aksoy, O., Lind, J., Vallet, S., Van der Vreken, A., Ates, G., Massie, A., Maes, K., De Veirman, K., De Bruyne, E., Vanderkerken, K., Podar, K., & Menu, E. (2025). PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism. Molecular Oncology.

Review article

2025

Popova, K., Benedum, J., Engl, M., Lütgendorf-Caucig, C., Fossati, P., Widder, J., Podar, K., & Slade, D. (2025). PARP7 as a new target for activating anti-tumor immunity in cancer. EMBO Molecular Medicine, 17(5), 872-888.

Review article

2025

Podar, K. (2025). Cure for multiple myeloma?. Memo - Magazine of European Medical Oncology, 18(2), 108-115.